Reported Highlights ECTRIMS 2019: Epidemiology & Treatment

A critical review by our ECF reporters of new data presented at ECTRIMS 2019 in Copenhagen in the fields of Epidemiology & Treatment

EACCME Accredited webinar

Now Playing: Reported Highlights ECTRIMS 2019: Epidemiology & Treatment

Gloria Dalla Costa, Gilles Edan, Pietro Annovazzi, Per Soelberg Sørensen - Dec 16, 2019

Welcome & introductions

  • Prof dr Giancarlo Comi, Chairman of the Department of Neurology and Director of the Institute off Experimental Neurology, Vita-Salute San Raffaele University, Milan, Italy

Report on Epidemiology

  • Dr Gloria Dalla Costa, MD, Clinical Research Unit on CNS Disorders and Clinical Neuroimmunology Research Unit, Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy
  • Prof dr Gilles Edan, Chair of the Department of Neurosciences, Neurological Department, University Hospital Rennes, Rennes, France

Report on Treatment

  • Dr Pietro Annovazzi, MD, UOC Centro SM - Neurologia II, ASST Valle Olona, Presidio Ospedaliero di Gallarate, Varese, Italy
  • Prof dr Per Soelberg Sörensen, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Report on Epidemiology (0:01:51 - 0:50:18)

Introduction (0:01:51 - 0:02:04)
Comorbidities (0:02:04 - 0:12:12)
  • A large exploratory case-control study on the multiple sclerosis prodrome, A. Hapfelmeier, Munich, Germany (0:02:04 - 0:07:24)
  • Cardiovascular disease in patients with multiple sclerosis: a nationwide cohort study in Sweden, F. Piehl, Stockholm, Sweden (0:07:24 - 0:09:40)
  • The survival of patients with multiple sclerosis in Turkey, M. Kurtuncu, Istanbul, Turkey (0:09:40 - 0:12:12)
Pregnancy (0:12:12 - 0:21:45)
  • Family planning decision making in people with multiple sclerosis, L. Lavorgna, Naples, Italy (0:12:12 - 0:15:42)
  • An international registry tracking pregnancy outcomes in women treated with dimethyl fumarate, K. Hellwig, Bochum, Germany (0:15:42 - 0:17:25)
  • Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and portpartum in women with MS, D. Landi, Rome, Italy (0:17:25 - 0:20:28)
  • Pregnancy outcomes in patients treated with Ocrelizumab, C. Oreja-Guevara, Lyon, France (0:20:28 - 0:21:45)
Long-term natural history studies (0:21:45 - 0:34:07)
  • 0:21:45 - 0:29:04: Long term outcomes. Changes in MS prognosis through the CIS Barcelona cohort: a 25-year tale (M. Tintore, Barcelona, Spain)
  • 0:29:04 - 0:34:07: Radiologically isolated syndrome: a 10 year follow-up study to identify factors predicting a clinical event (C. Lebrun, Nice, France)
Environmental risk factors (0:34:07 - 0:40:49)
  • 0:34:07 - 0:37:42: Serological response against HHV-6A is associated with increased risk for multiple sclerosis (A. Fogdell-Hahn, Stockholm, Sweden)
  • 0:37:42 - 0:40:49: A large case-control study on vaccination as risk factor of multiple sclerosis (C. Gasperi, Munich, Germany)
Questions, discussion and wrap-up (0:40:49 - 0:50:18)

Report on Treatment (0:50:18 - 1:49:33)

Introduction (0:50:18 - 0:52:46)
New therapies (0:52:46 - 1:11:13)
  • Efficacy and safety of Ofatumumab versus teriflunomide in RMS: phase 3 ASCLEPIOS I and II trials (0:52:46 - 0:58:33)
  • Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study (0:58:33 - 1:06:02)
  • Siponimod delays the time to wheelchair in atients with SPMS: results from the EXPAND study (1:06:02 - 1:07:52)
  • MESEMS: autologous mesenchymal stem cells for multiple sclerosis: a multi-center, randomized, double blind, cross-over phase 2 trial (1:07:52 - 1:11:13)
Lessons from registry studies (1:11:13 - 1:15:39)
  • Impact of age on treatment decisions and adherence to therapy in patients with relapsing-remitting MS (1:11:13 - 1:12:58)
  • Big multiple sclerosis data network: marginal structural models confirm the long-term impact of DMTs on disability progression (1:12:58 - 1:15:39)
Safety issues of MS therapies (1:15:39 - 1:26:52)
  • B-cell therapies related hypogammaglobulinemia (1:16:46 - 1:20:50)
  • PML (1:20:50 - 1:23:04)
  • Disease activity after FTY stop (1:23:04 - 1:26:52)
Pregnancy issues of MS therapies (1:26:52 - 1:30:22)
  • Fingolimod (1:26:52 - 1:28:08)
  • Natalizumab (1:28:08 - 1:30:22)
Therapeutic options in NMO-SD (1:30:22 - 1:39:44)
  • Inebilizumab (1:30:22 - 1:31:27)
  • Satralizumab (1:31:27 - 1:34:32)
  • Eculizumab (1:34:32 - 1:35:43)
  • Tocilizumab (1:35:43 - 1:39:44)
Questions, discussion and wrap-up (1:39:44 - 1:49:33)